

Bovilis® J-5

THE MASTITIS VACCINE WITH THE LOWEST LEVEL OF ENDOTOXIN ON THE MARKET.¹

BOVILIS® J-5 is a Gram-negative core-antigen vaccine that aids in the reduction of mastitis due to *Escherichia coli*.



Benefits of BOVILIS J-5:

- Reduces the rate of clinical coliform mastitis 2.4-fold greater than ENVIRACOR® J-5 during the first 100 days of lactation.²
- The greatest difference in efficacy over ENVIRACOR J-5 was in cows at higher risk – those third lactation and higher.²
- No negative effect on milk production.²

Proven to fight *E. coli* mastitis infections.²

Gram-negative infections from bacteria like *E. coli* can cause mastitis that leads to milk loss, culling and death. Core-antigen vaccines have been proven to reduce the frequency and severity of clinical coliform mastitis cases.³

The only brand with endotoxin level on the label.

Endotoxins, which are released from bacterial cell walls during vaccine manufacturing, can cause fever, loss of appetite, depression, shock, abortion and death. BOVILIS J-5 has the lowest endotoxin levels (EU/mL) of core-antigen vaccines on the market and is 15-fold below the U.S. Pharmacopeia (USP) recommendations.¹

	BOVILIS® J-5	ENDOVAC-DAIRY®	ENVIRACOR™ J-5	J-VAC®
Dose	5 mL	2 mL	5 mL	2 mL
Mean EU/mL	44 ^a	85,156 ^b	5,936 ^c	351,636 ^d

^{a,b,c,d}Means with different superscripts differ ($P < 0.05$).

¹ Comparison of endotoxin concentrations in BOVILIS® J-5 with those in three commercially available Gram-negative, lipopolysaccharide core-antigen vaccines, Merck Animal Health technical bulletin, 2020.

² Field trial to compare efficacy of BOVILIS® J-5 and ENVIRACOR® J-5 vaccines against clinical coliform mastitis during early lactation, Merck Animal Health technical bulletin, 2020.

³ Hogan JS, et al. Field trial to determine efficacy of an *Escherichia coli* J5 mastitis vaccine. *J Dairy Sci.* 1992; Vol. 75, No. 1.

⁴ Johnson AP, et al. Randomized noninferiority study evaluating the efficacy of 2 commercial dry cow mastitis formulations. *J Dairy Sci.* 2016;99:593-607.

⁵ Aruda AG, et al. Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations, Part 1. *J Dairy Sci.* 2013;96:4419-4435.

BOVILIS J-5: This product contains oil adjuvant. In the event of accidental self-injection, seek medical attention immediately. For additional information, see the product label.

ORBENIN-DC: For use in dry cows only. Do not use within four weeks (28 days) of calving. Treated animals must not be slaughtered for food purposes within 4 weeks (28 days) of treatment. For additional information, see the product label.

All trademarks are property of their respective owners.

Dry period protection now for a productive future.

The dry period is an important time to minimize mastitis risk and to vaccinate cows to protect their calves from scours. Along with BOVILIS J-5, help protect your herd with the use of:

- **ORBENIN-DC™** – dry cow mastitis treatment that targets Gram-positive bacteria which cause more than 94% of subclinical mastitis infections at dry-off.^{4,5}
- **SHUTOUT™** – an internal teat sealant that functions as a physical barrier to help prevent bacterial invasion of the teat canal.
- **GUARDIAN®** – the most complete scours vaccine with the broadest spectrum of protection against the four major bacterial and viral pathogens associated with scours in pre-weaned calves.

DOSAGE & ADMINISTRATION

- Administer 5 mL per cow via subcutaneous injection.
- Three doses are recommended at four- to six-week intervals. Do not vaccinate within two weeks of parturition.
- For complete directions and dosing regimen, refer to the package insert.

PRESENTATION

- Available in 250-mL bottle.

For more information, talk to your veterinarian or visit BovilisJ5.com.



 MADE IN THE USA

MAHCattle.com • 800-521-5767

© 2020 Intervet Inc., doing business as Merck Animal Health, a subsidiary of Merck & Co., Inc. All rights reserved. 11/20 US-BOV-20100002

